Crossmark

Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis

Crossref DOI link: https://doi.org/10.1136/openhrt-2018-000785

Published Online: 2018-07-03

Published Print: 2018-06

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Brunetti, Natale Daniele https://orcid.org/0000-0001-9610-7408
Tarantino, Nicola

De Gennaro, Luisa

Correale, Michele

Santoro, Francesco

Di Biase, Matteo
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02635230 at ClinicalTrials.gov

Documents that mention this clinical trial

Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis
https://doi.org/10.1136/openhrt-2018-000785

nct02866175 at ClinicalTrials.gov

Documents that mention this clinical trial

Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis
https://doi.org/10.1136/openhrt-2018-000785

nct02635230 at ClinicalTrials.gov

Documents that mention this clinical trial

Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis
https://doi.org/10.1136/openhrt-2018-000785

nct02866175 at ClinicalTrials.gov

Documents that mention this clinical trial

Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis
https://doi.org/10.1136/openhrt-2018-000785